|
COVID-19 vaccine commercialization is underway, and changes are happening fast! This means very soon, COVID-19 vaccines will be available to request for enrolled providers in the Adult Vaccine Program for patients without cost free coverage.
We anticipate that COVID-19 vaccine will be available in the IIS to order tomorrow, September 15th.
Once the COVID-19 vaccine is available to order through the Adult Vaccine Program, you may notice some differences from the pandemic COVID-19 Vaccine Program:
-
Only order what you can use and consider your storage capacity. Order quantities can be small with a minimum order size of ten.
-
Orders can be placed anytime throughout the month in the IIS.
-
All AVP accountability requirements apply to COVID-19 vaccines so ensure your temperature logs and inventory reports are up to date prior to placing your COVID-19 vaccine order.
-
Depots of COVID-19 vaccine are no longer allowed. Every provider should place their own COVID-19 vaccine order for shipment directly to their clinic for only the number of doses your clinic can use.
-
Waste will be tracked for COVID-19 vaccines now, so manage your stock accordingly and submit your vaccine returns when appropriate.
-
Ancillary kits will not be provided. Please ensure you have adequate supply on hand of all syringes, needles, and other ancillary supplies you may need to administer COVID-19 vaccine when it becomes available to order through the state programs.
-
COVID-19 vaccine available through the Adult Vaccine Program is for uninsured and underinsured individuals only. Underinsured: refers to a person who has health insurance, but the insurance does not cover COVID-19 vaccines; a person whose medical insurance does not provide first-dollar coverage (i.e., copay-free coverage) of COVID-19 vaccinations. All non-Covid-19 vaccines received through AVP are for uninsured individuals only.
-
COVID-19 vaccines will no longer ship within 48 hours but will now align with routine vaccine shipping timeframes.
Stay tuned to this newsletter as more important details develop!
If you were enrolled in the COVID-19 Vaccine Program and are transitioning to the Adult Vaccine Program, use this Transition Guide for COVID-19 Providers Moving to the AVP to assist you in successfully implementing the AVP in your practice.
For a quick comparison of Vaccine Program requirements between the COVID-19 vaccine program, Adult Vaccine Program, and Childhood Vaccine Program here is a chart showing the similarities and differences.
There is still time to enroll in the Adult Vaccine Program (AVP) to be eligible to request COVID-19 vaccine for your patients. Providers who enroll now will also be eligible to request other routine vaccines in the next AVP vaccine order cycle in Spring 2024.
You can use the Adult Vaccine Provider Enrollment Guide (PDF) to help you through the enrollment process.
Hot off the press! ACIP met to vote on recommendations for the 2023-24 COVID-19 vaccines. They voted in favor of recommending these new monovalent COVID-19 vaccines including the XBB.1.5 component:
· Everyone 5 years and older without immunocompromise is recommended to receive 1 dose of 2023-2024 COVID-19 vaccine regardless of prior vaccination history.
· Children ages 6 months-4 years should complete a multi-dose initial series (2 doses of Moderna or 3 doses of Pfizer-BioNTech mRNA COVID-19 vaccine) with at least one dose of 2023-2024 COVID-19 vaccine.
· People who are moderately or severely immunocompromised should complete a 3-dose initial series with at least one dose of the 2023-2024 COVId-19 vaccine and may receive 1 or more additional 2023-2024 COVID-19 vaccine doses.
· Bivalent mRNA COVID-19 vaccines are no longer recommended (or authorized for use) in the United States.
Vaccines are being sent out through distribution and should be available soon. More detailed guidance will be available on the Interim Clinical Considerations For Use of COVID-19 in the US webpage in the next few days. You can find a copy of the materials presented at the ACIP meeting at the following link:
ACIP September 12, 2023 Presentation Slides | Immunization Practices | CDC
There will be two* different COVID-19 products available to order now through the Adult Vaccine Program.
Adult COVID-19 CDC Vaccine Price List:
 *Novavax COVID-19 vaccine for individuals 12 and older is still pending FDA approval and will be available to order at a later date.
Please note that some presentations require ultra-cold storage capability. Please order only what your clinic is able to store and administer according to these requirements. If you have an additional storage unit to add to your AVP provider agreement to store COVID-19 vaccines, please request your agreement be returned to you for edits.
More detailed product guides coming soon!
As part of FDA’s actions, the bivalent Moderna and Pfizer-BioNTech COVID-19 vaccines are no longer authorized for use in the United States. To minimize the risk of vaccine administration errors, providers should:
- Remove all bivalent mRNA COVID-19 vaccines from storage units immediately, even if they are not expired.
- Dispose of all bivalent mRNA COVID-19 vaccine vials in accordance with local, state, and federal regulations.
- Report all disposed inventory as wastage.
Remove Bivalent mRNA COVID-19 Vaccines from Your Inventory
The table below provides a listing of COVID-19 bivalent vaccines that should be removed from your inventory. For additional information, see IIS COVID-19 Vaccine Related Code | CDC.
Please make sure you join the very timely and important Training Series session on Thursday, September 21st. This topic will include all the information you need to know for COVID-19 vaccine storage and handling requirements. Please make time to join this training session and bring all your questions!
Date: September 21, 2023
Time: 12:00 pm (noon)
Topic: Storage and Handling Requirements for COVID-19 Vaccine
Intended Audience: Providers and Vaccine Coordinators
This training session will be recorded and posted to our training webpage.
Any COVID-19 vaccine obtained after commercialization, shall use the code/funding structure below:
-
Bridge Vaccine – Dose Eligibility V23 and Funding Source VXC50
-
Publicly Supplied AVP vaccine – Dose Eligibility V23; Funding Source VXC52.
- Pharmacy Program – Dose Eligibility V01 and Funding Source VXC50 or VXC52
- Patient eligibility and funding codes shall align with the state eligibility guide for all other COVID-19 vaccines.
- Publicly Supplied VFC vaccine (state supplied VFC vaccine) – Dose Eligibility V02, V03, V04, and V05; Funding Source VXC51.
- Public Supplied Non-VFC vaccine (state supplied vaccines provided to CHIP and/or privately insured children) – Dose Eligibility V22 or V25; Funding Source VXC52.
- Privately Purchased vaccine (vaccine purchased outside of these programs) – Dose Eligibility V01 and V24; Funding Source PHC70.
We recommend vaccine clinic staff reach out to their EHR and IT support teams to be sure any system updates needed to support these changes are identified.
Pneumococcal and Adult RSV Vaccine Webinar Recordings Available with CEs
Two webinars hosted by CDC are now available as recordings. Continuing education credits are available for watching the recording.
2023-2024 Influenza Vaccine Recommendations Published
CDC recently published Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023–24 Influenza Season. The primary change is the guidance that people with egg allergy of any severity may receive any influenza vaccine with standard precautions.
- Any influenza vaccine (egg based or nonegg based) appropriate for the recipient’s age and health status can be used.
- Egg allergy alone necessitates no additional safety measures for influenza vaccination beyond those recommended for any recipient of any vaccine, regardless of severity of previous reaction to egg.
- All vaccines should be administered in settings in which rapid treatment of acute hypersensitivity reactions is available.
|
